Edgar Tapia

Edgar Tapia

PhD Candidate

Research Advisor:

Sherry Chow

Research Topic:

Phase II Clinical Trial of Metformin to Reduce Obesity Associated Breast Cancer Risk

Selected Publications:

Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors. Amin AD, Rajan SS, Liang WS, Pongtornpipat P, Groysman MJ, Tapia EO, Peters TL, Cuyugan L, Adkins J, Rimsza LM, Lussier YA, Puvvada SD, Schatz JH.

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Amin AD, Li L, Rajan SS, Gokhale V, Groysman MJ, Pongtornpipat P, Tapia EO, Wang M, Schatz JH.

Selected Awards/Honors:

Initiative for Maximizing Student Development (IMSD), 2014
T32 Cancer Biology Training Grant, 2017
GMaP Travel Award, 2018

Selected Presentations:

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved. New Orleans, LA. November 2018, Breast Density and Metabolic Risk Factors: Cross-sectional Analysis of the Baseline Data from a Phase II Breast Cancer Prevention Trial

Cancer Biology Student Colloquium, August 2018, Tucson, Az. Phase II Clinical Study for Breast Cancer Prevention


  • Universidad de Sonora, Bachelors, Biology, 2012